Small study to uncover how psoriasis drug tames the immune system
NCT ID NCT05390515
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how the drug tildrakizumab changes immune cells in the skin and blood of people with moderate-to-severe psoriasis. Ten adults will be treated and monitored for three months. The goal is to see how the drug reduces psoriasis severity and what happens to immune function during treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tildrakizumab (an IL-23 blocker given by injection)
- What this could lead to
- If successful, this could help doctors understand how tildrakizumab works in the body to control psoriasis, potentially improving treatment strategies.
- What could go wrong
- This is a very small early-phase study with only 10 participants, so results may not apply to everyone. It focuses on immune changes, not long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS VULGARIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an ancient herbal mix tame psoriasis flares?
- Psoriasis drug trial aims to calm overactive immune cells
- Diabetes drug cream shows promise for psoriasis in new trial
- Blood test may end guesswork in psoriasis dosing
- New study to measure psoriasis treatment success beyond the skin
- Could a plant cream soothe psoriasis? new trial tests it